Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

Tuesday, February 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals announced that it will report its fourth quarter and full year 2023 financial results on March 5, 2024. Following the report, a conference call and webcast will take place to discuss the results and provide a business update. Interested participants can join the call via phone or online, with the webcast available for replay for 90 days after the event.
Price reaction · baseline $14.2 (2024-02-26 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close
+5.6%
day 1 · peak
+9.2%
day 3
+9.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel will report its financial results and business update soon.
  • The company is actively engaging with investors through a conference call and webcast.
  • Rigel continues to focus on improving therapies for patients with hematologic disorders and cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Investors & Media Contact
Rigel Pharmaceuticals, Inc.
Email: [email protected]

Frequently Asked Questions

When will Rigel report its Q4 2023 financial results?

Rigel will report its fourth quarter financial results on March 5, 2024.

How can I access Rigel's conference call?

You can dial 877-407-3088 for domestic or 201-389-0927 for international access.

Where will the conference call be held?

The conference call will be held at 4:30 p.m. Eastern Time.

Will the conference call be available for replay?

Yes, the call will be archived for 90 days after the live broadcast.

What is Rigel Pharmaceuticals focused on?

Rigel focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare financial results conference call business update quarterly earnings
Last updated: Feb 27, 2024

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →